Emcure Pharmaceuticals (EMCURE) Stock Overview
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for EMCURE from our risk checks.
EMCURE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Emcure Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,339.90 |
| 52 Week High | ₹1,532.95 |
| 52 Week Low | ₹889.00 |
| Beta | 0 |
| 1 Month Change | -2.30% |
| 3 Month Change | 7.00% |
| 1 Year Change | -6.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.42% |
Recent News & Updates
These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well
Sep 27
Expansion In Chronic Therapies And Emerging Markets Will Thrive
Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.Recent updates
These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well
Sep 27Expansion In Chronic Therapies And Emerging Markets Will Thrive
Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report
May 25Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark
May 16Emcure Pharmaceuticals Limited (NSE:EMCURE) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Feb 15We Think Emcure Pharmaceuticals (NSE:EMCURE) Can Stay On Top Of Its Debt
Jan 06Shareholder Returns
| EMCURE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.3% | -0.7% | -0.6% |
| 1Y | -6.1% | -7.2% | -6.0% |
Return vs Industry: EMCURE exceeded the Indian Pharmaceuticals industry which returned -7.2% over the past year.
Return vs Market: EMCURE matched the Indian Market which returned -6% over the past year.
Price Volatility
| EMCURE volatility | |
|---|---|
| EMCURE Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: EMCURE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: EMCURE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 6,731 | Satish Mehta | www.emcure.com |
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names.
Emcure Pharmaceuticals Limited Fundamentals Summary
| EMCURE fundamental statistics | |
|---|---|
| Market cap | ₹253.92b |
| Earnings (TTM) | ₹7.44b |
| Revenue (TTM) | ₹81.81b |
Is EMCURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMCURE income statement (TTM) | |
|---|---|
| Revenue | ₹81.81b |
| Cost of Revenue | ₹33.41b |
| Gross Profit | ₹48.40b |
| Other Expenses | ₹40.96b |
| Earnings | ₹7.44b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 39.27 |
| Gross Margin | 59.16% |
| Net Profit Margin | 9.10% |
| Debt/Equity Ratio | 22.0% |
How did EMCURE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 23:45 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Emcure Pharmaceuticals Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Foram Parekh | BOB Capital Markets Ltd. |
| null null | BOB Capital Markets Ltd. |
| Alok Dalal | Jefferies LLC |